ION expands ETF trading capabilities with Tradeweb integration
Artivion NASDAQ:AORT President and CEO James P. Mackin sold 34,210 shares of common stock on November 13, 2025, at a price of $45.858, for a total transaction value of $1,568,802. The transaction occurred with AORT trading near its 52-week high of $48.04, having delivered an impressive 68.9% return over the past year according to InvestingPro data.
Following the transaction, Mackin directly owns 800,993 shares of Artivion. The medical device company currently has a market capitalization of approximately $2.1 billion and is expected to become profitable this year despite posting a loss over the last twelve months.
In other recent news, Artivion Inc. reported impressive third-quarter results for 2025, with earnings per share reaching $0.16, significantly surpassing the forecast of $0.03. The company also achieved revenues of $113.4 million, exceeding both the consensus estimate of $110.44 million and Oppenheimer’s estimate of $112 million. This strong performance led Artivion to raise its revenue and EBITDA guidance for the full year 2025. As a result of these positive earnings, Oppenheimer increased its price target for Artivion to $50, maintaining an Outperform rating. Needham also raised its price target on the company to $58, keeping a Buy rating. These adjustments reflect the analysts’ confidence in Artivion’s growth potential following the earnings beat. The company’s robust financial performance highlights its strong position in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.